Evidence map›Paper›PMID 35538928›Full record

ArticleJournal of infectious disease and therapy2019

Insulin Resistance is Associated with Higher Plasma Viral Load Among HIV-Positive Adults Receiving Longer-Term (1 Year) Combination Antiretroviral Therapy (ART).

L B Mulenga, P Musonda, L Chirwa, M Siwingwa, A Mweemba, S Suwilanji, S Fwoloshi, H Phiri, D Phiri, P L Mulenga and 14 more

Abstract read
In one paragraph

Article in Journal of infectious disease and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

L B MulengaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
P MusondaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
L ChirwaUniversity Teaching Hospital, Adult Infectious Diseases Center, Lusaka, Zambia.
M SiwingwaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
A MweembaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
S SuwilanjiUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
S FwoloshiUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
H PhiriMinistry of Health, Ndeke House, Lusaka, Zambia.
D PhiriMinistry of Health, Ndeke House, Lusaka, Zambia.
P L MulengaMinistry of Health, Ndeke House, Lusaka, Zambia.
T ChisengaMinistry of Health, Ndeke House, Lusaka, Zambia.
R NsakanyaMinistry of Health, Ndeke House, Lusaka, Zambia.
A ShibembaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
J ToddLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
S NzalaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
T KaileUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
C KankasaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
L HachaambwaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
C ClaassenUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
I SikazweUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
J R KoetheVanderbilt University Medical Center (VUMC), Department of Medicine, Division of Infectious Diseases, Nashville, TN, USA.
E SinkalaUniversity of Zambia, School of Medicine, Division of Infectious Diseases, Internal Medicine, Lusaka, Zambia.
D C HeimburgerVanderbilt University Medical Center (VUMC), Department of Medicine, Division of Infectious Diseases, Nashville, TN, USA.
C W WesterVanderbilt University Medical Center (VUMC), Department of Medicine, Division of Infectious Diseases, Nashville, TN, USA.

Funding

UNZA-Vanderbilt Training Partnership for HIV-NCD Research (UVP-2)D43TW009744 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMBURGER, DOUGLAS CORBETT, MUTALE, WILBROAD · 2015 to 2025
$3.2M
FIC NIH HHS D43 TW009744
6 · The paper itself

Abstract

Background: As HIV-positive persons survive longer due to the success of combination antiretroviral therapy (ART) in decreasing mortality, the burden of non-communicable diseases including diabetes mellitus (DM) is anticipated to rise. HIV is characterized by systemic inflammations, markers of which decrease quickly following ART initiation, but typically do not completely normalize. Inflammation may be accompanied by insulin resistance (IR), and both are implicated in the pathogenesis of DM in HIV-positive individuals. Sub-Saharan Africa accounts for almost two-thirds of the global HIV burden but there are few reports of IR, DM and HIV in this region. We assessed the relationship between IR and viral suppression among HIV-positive adults in the Zambian national ART program. Methods: We conducted a cross-sectional survey evaluating HIV-positive adults that had received first line ART (usually TDF/FTC/EFV) for 12 months (± 3 months). Twenty clinics were sampled systematically based on the random starting-point, sampling interval and cumulative population size. Eligible patients had plasma viral load (VL), fasting insulin, and glucose performed. Insulin resistance was determined using Homeostatic model assessment (HOMA). We determined proportions for each outcome using linearized standard error 95% confidence intervals and summary estimates. Viral suppression was defined according to the detection threshold of<20 copies/mL and treatment failure was defined as VL>1,000 copies/mL. Results: Of 473 patients enrolled, 46.8% were male and 53.2% were female. 142 (30%) [95% CI: 0.26-0.34] had IR. Among those with IR, 55 (38.7%) were male whereas 87 (61.3%) were female (p value=0.104). 19% of individuals with IR had treatment failure compared to 5.7% without IR (p value<0.0001). 427 (90.3%) participants had treatment success (VL<1,000 copies/mL), and this was associated with a lower likelihood of IR (odds ratio (OR)=0.26 [0.14, 0.48], p value<0.0001). In addition, a significantly lower proportion of patients with IR were virologically suppressed at one-year compared to individuals without IR, 58% [0.54-0.70] versus 70% [0.65-0.75], respectively (p value=0.042). Conclusion: In Zambian adults on ART for a year, the development of insulin resistance was strongly associated with suboptimal HIV outcomes, specifically non-viral suppression and treatment failure. Further investigations are warranted to determine if this positive association between IR and VL is causally related, and if so in which direction.

Indexed as

Combination antiretroviral therapyInsulin resistanceTreatment failureViral suppressionZambia

Identifiers

PMID35538928
PMCPMC9082628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.